ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

India approves 2 more COVID vaccines, Merck's antiviral drug

Inoculation to be expanded to 15-18 age group in anticipation of omicron wave

India has approved molnupiravir to treat adult patients.   © Reuters

NEW DELHI -- India is stepping up defenses against a possible third wave of coronavirus infections caused by omicron by implementing a slew of measures, including approving two more vaccines as well as Merck's COVID-19 pill, and expanding its inoculation drive to those aged 15 to 18.

India's Minister of Health Mansukh Mandaviya tweeted on Tuesday that the country "has given 3 approvals in a single day" for the Corbevax and Covovax vaccines, and antiviral drug molnupiravir for restricted use.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more